GALEAS Tumor

Enhanced comprehensive genomic profiling (CGP) of clinically relevant biomarkers regardless of tumor origin at your fingertips

Consolidate CGP testing into one streamlined NGS workflow, from sample to data analysis

Cancer is a complex and heterogeneous disease that is a leading cause of death worldwide, with approximately 375,000 new cases reported in the UK each year. Breast, prostate, lung, and bowel cancers are responsible for over half of all new cancer cases. Understanding the various types and subtypes of cancer, as well as the genetic abnormalities that drive individual cancers, is crucial for effective diagnosis and treatment.1,2

Tissue origin is not always an indicator of the genetic profile of a cancer. Broad profiling of SNVs, INDELs and CNVs combined with the use of prognostic biomarkers including microsatellite instability (MSI) status and tumor mutational burden (TMB), provides scientists and clinicians with a comprehensive malignancy profile. This delivers clinically actionable information and ensures rapid access to the most appropriate treatment and therapeutic strategies. However, covering this range of biomarkers can require the use of multiple testing workflows putting burden on laboratory resources.

Consolidating testing of different biomarkers and different cancer types into a single workflow enables genetic testing laboratories to streamline processes reducing turn-around times and cost burdens; resulting in faster patient results, quicker diagnoses and treatment decisions, all of which improves patient outcomes

1 Ciriello G., Miller ML., Askoy BA., Senbabaoglu Y., Schultz N., Sander C. “Emerging landscape of oncogenic signatures across human cancers.” Nature genetics (2013): 1127-1133.
2 The ICGC/TCGA PanCancer Analysis of Whole Genomes Consortium. “Pan-cancer analysis of whole genomes.” Nature (2020): 82-93.
In the Hospital Doctors and Nurse Standing at the Reception
Two Scientists Collaborating at a Computer

Truly comprehensive in design, GALEAS Tumor offers laboratories a single workflow for genomic profiling of a wide range of common cancer biomarkers, including hereditary and pediatric, regardless of tumor origin.

GALEAS Tumor

The enhanced content of GALEAS Tumor combined with optimised bioinformatics enables scientists and clinicians to confidently detect a wide range of gene aberrations known to drive cancer, from SNVs, INDELs, selected fusions and genome-wide CNVs, to biomarkers for TMB and MSI across 519 genes.

Whilst exon focused, the panel design covers key intronic and promoter regions and contains a CNV backbone to support copy number calling across the genome. It is a comprehensive panel that allows the profiling and accurate identification of variants associated with cancer to stratify all common cancers in a single workflow.

E

GALEAS Tumor leverages ultra-sensitive targeted NGS chemistry pioneered by Nonacus to maximize sequencing efficiency.

E

It delivers a high percentage of on-target reads, with superior uniformity of coverage ensuring exceptional technical performance and delivering high recall and precision across detected variants.

E

By enabling the sequencing of more on-target DNA using less sequencing resource, Nonacus achieves higher content with reduced resource requirements, resulting in a revolutionary approach to comprehensive genetic analysis.

Key quality indicator GALEAS Tumor
Number of Genes 519
Capture Panel size (Mb) 3.74Mb
Gb required for mean 500x coverage 5Gb
Percentage coverage ≥250x 98%
Percentage on or near bait 71%
Percent duplication 9%
SNV recall 100%
INDEL Recall 100%

GALEAS Tumor demonstrates unrivalled robust and accurate variant calling for primary tumor profiling of FFPE DNA, validating its position as a reliable solution for precise genetic analysis in the field of tumor profiling

Delivering clinical precision:

GALEAS Tumor confidently identifies somatic variants with 100% recall and precision

GALEAS Tumor confidently identified somatic variants in a colorectal cancer (CRC) cohort with 100% recall and precision (Figure 1). The efficacy of the GALEAS Tumor workflow was assessed using reference material from FFPE containing 23 SNVs and INDELs that had previously been confirmed by ddPCR.

A strong correlation between NGS and ddPCR- determined VAFs was observed with a mean depth of 500x (R2 = 0.99) (Figure 2).

Oncoplot from 50 CRC FFPE cohort highlighting detection of somatic mutations in genes with known cancer hotspots

Figure 1. Oncoplot from 50 CRC FFPE cohort highlighting detection of somatic mutations in genes with known cancer hotspots

SNV and INDEL recall rate for alterations in reference material from FFPE

Figure 2. SNV and INDEL recall rate for alterations in reference material from FFPE

Unveiling copy number insights:

GALEAS Tumor delivers precision CNV detection

The design of GALEAS Tumor incorporates a copy number backbone targeting informative genome wide SNPs enabling enhanced CNV calling to a >1Mb resolution.

Strong correlation of GALEAS Tumor SNP backbone data with shallow whole genome sequencing (sWGS) demonstrates its efficacy as a reliable tool for comprehensive CNV analysis in clinical genomic profiling (Figure 3). ​

Samples with varying copy numbers were assessed using GALEAS Tumor. The three samples assessed had known copy number variations in EGFR and MET that consist of 3, 6 and 12 copies. They were quantitatively confirmed by GALEAS Tumor, leveraging the genome-wide SNP backbone design (Figure 4).

Validating gene level CNV calls with a CNV Lung and Brain Mix reference standard

Figure 4. Validating gene level CNV calls with a CNV Lung and Brain Mix reference standard at (A) 12, (B) 6, and (C) 3 copies. Genes highlighted here are EGFR and MET.

Comparison of GALEAS Tumor SNP backbone data with sWGS for a representative colorectal cancer sample

Figure 3. Comparison of GALEAS Tumor SNP backbone data with sWGS for a representative colorectal cancer sample

Empowering access to immunotherapy treatment:

GALEAS Tumor delivers a combined tumor genomic instability measurement for TMB and MSI

GALEAS Tumor demonstrates excellent utility as a solution for the determination of MSI scoring and TMB status, offering a clinically viable solution to help match patients with appropriate immunotherapies. ​

​GALEAS Tumor correctly identified 100% of MSS (microsatellite stable) and normal samples, and 23/24 MSI-H (microsatellite instability-high) CRC samples evaluated (Figure 5). ​

TMB is a key immuno-oncology biomarker across multiple cancer types and has been shown to correlate strongly with MSI status in colorectal cancer 3, 4. A strong correlation was observed between the GALEAS Tumor derived TMB scores for a CRC cohort (Median TMB 28.24, log2 TMB 1.45) and corresponding sample MSI status (Figure 6).

3 https://doi.org/10.1002/ijc.32002 Endris V, Buchhalter I, Allgäuer M et al. Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: In-silico and real-life analysis of three larger gene panels. Int J Cancer 2019; 144: 2303– 2312.
4 https://www.annalsofoncology.org/article/S0923-7534(19)31240-2/fulltext

Comparisons of GALEAS Tumor MSI scores with known MSI status from CRC primary tumor samples (MSS-High), healthy individuals (MSS) and reference standards

Figure 5. Comparisons of GALEAS Tumor MSI scores with known MSI status from CRC primary tumor samples (MSS-High), healthy individuals (MSS) and reference standards.

GALEAS™ Tumor TMB scores across 50 CRC samples compared with MSI

Figure 6. GALEAS Tumor TMB scores across 50 CRC samples compared with MSI

Access to the cloud-based GALEAS Analysis Software delivers a comprehensive variant calling pipeline

Cutting-edge bioinformatics pipelines are included with GALEAS Tumor. This cloud-based software solution has been specifically tailored and optimized for secondary calling, guaranteeing a robust and accurate analysis of somatic variants. This is critical to ensuring reliable downstream interpretation analysis and providing clinicians with reliable data to help them make informed decisions regarding patient care and treatment strategies.

In line with the dynamic field of immuno-oncology, our software provides invaluable insights into tumor biology and profiling incorporating essential biomarkers such as TMB and MSI, which are crucial for tumor characterization and treatment decisions. These biomarkers enable personalized medicine approaches and informed clinical decision support.

Experience the analytical power of GALEAS Analysis Software for variant calling to optimise genomic data interpretation to new levels of excellence.

Abstract DNA strand and doctor using tablet for software analysis

Features of GALEAS Tumor

E

Extensive common cancer content including hereditary and pediatric cancer

E

Common driver mutations including SNVs, CNVs and INDELs in 519 genes

E

Enhanced coverage of the 1p/19q codeletion associated with Glioma

E

CNV backbone enabling enhanced CNV calling to a >1Mb resolution

E

Probes for MSI and TMB Immuno-oncology biomarker scoring

E

Fusion/Structural rearrangements​ including: ALK, BRAF, EGFR, FGFR2, FGFR3,​ NTRK1, NTRK2, RET, ROS1, TMPRSS2

E

Identity tracking SNPs

E

64 Pharmacogenomics (oncology) SNPs

E

HLA genes relevant for solid tumors

Why choose GALEAS Tumor?

Enhanced, current and clinically relevant content

Expertly curated content with 100% UK test directory coverage enabling the profiling of key clinically relevant biomarkers across 519 genes. Comprehensive in design, GALEAS Tumor allows the profiling and accurate identification of variants associated with cancer to stratify all common cancers in a single workflow.

Reliably and robustly detect CNVs

Whilst exon focused, GALEAS Tumor covers key intronic and promoter regions and contains a CNV backbone enabling enhanced CNV calling to a >1Mb resolution to support copy number calling across the genome.

Supported by GALEAS Analysis Software

Optimized for GALEAS panels, our cloud-based bioinformatics pipelines deliver accurate calling of SNPs, INDELs and CNVs associated with all common cancers.

The GALEAS Analysis Software has also been designed for the analysis of both TMB and MSI.

The GALEAS Tumor workflow is simple and easy

Taking less than 10 hours, with less than 2 hours hands-on time, it is designed with multiple stop points to provide flexibility within laboratory processing. Library preparation can be run manually or automated for up to 96 samples in a single run. Indexes are available for up to 384 samples to allow for flexible batch sizes and scalability across all Illumina benchtop sequencers .

FFPE Block

gDNA, FFPE DNA samples

Wide range of sample types including FFPE, frozen tissue and blood

DNA strand

Prepare samples

BeadXtract DNA extraction kits

GALEAS Tumor

Prepare libraries and enrich

GALEAS Tumor

Illumina NGS sequencing system

Sequence

Illumina NGS Sequencing System

GALEAS Analysis Software

Call variants

GALEAS Analysis Software

Tertiary software for interpretation and reporting

Interpret and report

Utilize third party tertiary software for interpretation and reporting

Interested in adding GALEAS Tumor as a test in your laboratory?

Product Resources

GALEAS Tumor Protocol [PDF]
GALEAS Tumor Poster [PDF]

Panel Specifications

Parameters Specification
Enrichment method Hybridization and capture
Number of genes 519
Capture Panel size 3.74Mb
Sequencing platform Illumina
Targets Genes associated with common cancers
Variant types SNVs, CNVs and INDELs
Input DNA requirements 10ng-200ng
Sample type gDNA from FFPE, frozen tissue or blood
Multiplexing guidance for sequencing 25M reads per sample required to achieve 500x. This equates to 5Gb per sample

Ordering Information

Product Name Pack Size Catalogue Number Description
GALEAS Tumor Kit Frag A 
(96 samples)
96 NGS_GAL_TCP_FR_96_A Includes adaptor plate A (1-96 indexes) and complimentary analysis of FASTQ files using GALEAS analysis software for up to 96 samples. NOTE: Further charges may apply for reanalysis or reprocessing of FASTQ files, or storage beyond the data retention policy set out in the Terms & Conditions.
GALEAS Tumor Kit Frag B
(96 samples)
96 NGS_GAL_TCP_FR_96_B Includes adaptor plate B (97-192 indexes) and complimentary analysis of FASTQ files using GALEAS analysis software for up to 96 samples. NOTE: Further charges may apply for reanalysis or reprocessing of FASTQ files, or storage beyond the data retention policy set out in the Terms & Conditions.
GALEAS Tumor Kit Frag C
(96 samples)
96 NGS_GAL_TCP_FR_96_C Includes adaptor plate C (193-288 indexes) and complimentary analysis of FASTQ files using GALEAS analysis software for up to 96 samples. NOTE: Further charges may apply for reanalysis or reprocessing of FASTQ files, or storage beyond the data retention policy set out in the Terms & Conditions.
GALEAS Tumor Kit Frag D
(96 samples)
96 NGS_GAL_TCP_FR_96_D Includes adaptor plate D (289-384 indexes) and complimentary analysis of FASTQ files using GALEAS analysis software for up to 96 samples. NOTE: Further charges may apply for reanalysis or reprocessing of FASTQ files, or storage beyond the data retention policy set out in the Terms & Conditions.
GALEAS Tumor Kit Frag
(16 samples)
16 NGS_GAL_TCP_FR_16 Includes adaptor plate (1-16 indexes) and complimentary analysis of FASTQ files using GALEAS analysis software for up to 16 samples. NOTE: Further charges may apply for reanalysis or reprocessing of FASTQ files, or storage beyond the data retention policy set out in the Terms & Conditions.

Thank you for your interest in GALEAS Tumor